Fig. 5: Evolution of Treg therapies.
From: Harnessing the biology of regulatory T cells to treat disease
Over the last 10 years, regulatory T (Treg) cell-directed therapies have primarily focused on in vivo (red) or polyclonal adoptive cell therapy-based ex vivo approaches (blue) to enhance disease-relevant function. These first-generation approaches are consistently safe but there are significant current challenges such as a lack of antigen specificity and poor control over the ultimate effects. The field is rapidly moving to next-generation approaches focused on more precise and specific Treg cell targeting using protein engineering and nanomedicines for in vivo targeting and gene engineering for optimal adoptive cell therapy approaches. CAR, chimaeric antigen receptor; TCR, T cell receptor.
